DailySpaceSolution Group Berhad
0093 · ACE Market创业板（ACE Market） · annual reports 2023 to 2025, 1380 entries read2023 至 2025 年报，共读出 1380 条
The company这家公司
Solution Group operates across engineering equipment under the SOLTEQ brand, industrial automation and plant construction, metal fabrication and assembly, green and renewable energy, biopharmaceuticals and biotechnology, and industrial lubricants under the SOLMAX brand. The group has 2 manufacturing sites, 1 located in Selangor and 1 in Kuala Lumpur.Solution Group 经营的业务包括 SOLTEQ 品牌的工程设备、工业自动化与厂房建设、金属制造与组装、绿色与可再生能源、生物制药与生物技术，以及 SOLMAX 品牌的工业润滑油。集团拥有 2 处制造基地，1 处位于雪兰莪，1 处位于吉隆坡。
Source: annual report 2024, pages 17, 19; annual report 2025, pages 14, 17.出处：2024 年年报第 17、19 页；2025 年年报第 14、17 页。
In 2023 and 2024, industrial automation and plant construction accounted for 85.89% and 77.24% of revenue. In 2025, engineering equipment became the largest segment at 48.02% (RM13.8 million), while industrial automation and plant construction accounted for 20.56% (RM5.9 million), metal fabrication and assembly 14.71%, solar business 7.69%, biopharmaceutical and biotechnology 5.70%, and industrial lubricants 3.32%.2023 与 2024 年，工业自动化与厂房建设分别占营业额的 85.89% 和 77.24%。2025 年，工程设备成为最大部门，占 48.02%（RM13.8 million），而工业自动化与厂房建设占 20.56%（RM5.9 million），金属制造与组装占 14.71%，太阳能业务占 7.69%，生物制药与生物技术占 5.70%，工业润滑油占 3.32%。
Source: annual report 2023, page 16; annual report 2024, page 16; annual report 2025, pages 15, 17.出处：2023 年年报第 16 页；2024 年年报第 16 页；2025 年年报第 15、17 页。
In 2025, revenue from Malaysia was RM27,120,348 and outside Malaysia RM1,553,966. In 2024, Customer A contributed RM56,448,086 and Customer B contributed RM20,944,859, both in industrial automation services. In 2025, Customer A contributed RM4,603,915 in industrial automation services and Customer B contributed RM3,099,099 in green and renewable energy. At end 2025, 2 major customers represented approximately 61% of total trade receivables.2025 年，来自马来西亚的营业额为 RM27,120,348，来自其他国家为 RM1,553,966。2024 年，客户 A 贡献 RM56,448,086，客户 B 贡献 RM20,944,859，皆属于工业自动化服务。2025 年，客户 A 在工业自动化服务中贡献 RM4,603,915，客户 B 在绿色与可再生能源中贡献 RM3,099,099。截至 2025 年底，2 家主要客户占应收账款总额约 61%。
Source: annual report 2024, page 123; annual report 2025, pages 130, 137.出处：2024 年年报第 123 页；2025 年年报第 130、137 页。
At end 2025, Lim Yong Hew held 67,680,377 shares directly (13.982%) and 19,826,733 shares indirectly (4.096%) through immediate family members and Solvest Sdn. Bhd. Lim Yong Hew is the uncle of executive director Lim Chiou Kim. Datuk Dr. Syed Muhamad Bin Syed Abdul Kadir has no family relationship with any director or major shareholder.截至 2025 年底，Lim Yong Hew 直接持有 67,680,377 股（13.982%），并通过直系亲属及 Solvest Sdn. Bhd. 间接持有 19,826,733 股（4.096%）。Lim Yong Hew 是执行董事 Lim Chiou Kim 的叔父。Datuk Dr. Syed Muhamad Bin Syed Abdul Kadir 与任何董事或主要股东均无亲属关系。
Source: annual report 2025, pages 6, 10, 63, 152.出处：2025 年年报第 6、10、63、152 页。
On 1 December 2024, Lim Yong Hew was redesignated as Deputy Executive Chairman, and Dato' Dr. Mohd Nazlee Bin Kamal was redesignated as Group Chief Executive Officer. On 16 April 2026, Lim Yong Hew was redesignated as Executive Chairman, and Datuk Dr. Syed Muhamad Bin Syed Abdul Kadir was redesignated as Non-Independent Non-Executive Director.2024 年 12 月 1 日，Lim Yong Hew 调任为执行副主席，Dato' Dr. Mohd Nazlee Bin Kamal 调任为集团首席执行员。2026 年 4 月 16 日，Lim Yong Hew 调任为执行主席，Datuk Dr. Syed Muhamad Bin Syed Abdul Kadir 调任为非独立非执行董事。
Source: annual report 2024, pages 7, 8; annual report 2025, pages 3, 6, 7.出处：2024 年年报第 7、8 页；2025 年年报第 3、6、7 页。
Revenue by segment, 20252025 年各部门营业额占比
Source: annual report 2025, page 17.出处：2025 年年报第 17 页。
Major events大事记
Source: annual report 2023, page 87.出处：2023 年年报第 87 页。
Source: annual report 2023, page 47; annual report 2024, page 48.出处：2023 年年报第 47 页；2024 年年报第 48 页。
Source: annual report 2024, page 51.出处：2024 年年报第 51 页。
Source: annual report 2024, page 89.出处：2024 年年报第 89 页。
Source: annual report 2024, pages 7, 8.出处：2024 年年报第 7、8 页。
Source: annual report 2025, page 57.出处：2025 年年报第 57 页。
Source: annual report 2025, pages 3, 6.出处：2025 年年报第 3、6 页。
Revenue and profit before taxation营业额与税前盈利（亏损）
Total assets, total equity and borrowings总资产、总权益与借款
20232023 年
In 2023, the company raised RM8,573,877 by issuing 43,968,600 new shares via private placement at RM0.195 per share for working capital. Net cash used in operating activities was RM1,629,799. Borrowings included RM2,606,210 drawn from banker's acceptance, while net repayment of term loans was RM475,055 and repayment of lease liabilities was RM586,149. Capital spending was RM80,720 for property, plant and equipment and RM9,272 for right-of-use assets. A subsidiary acquired Solution BioResearch Sdn. Bhd. for RM1. Net placement of deposits under lien was RM452,528, bringing fixed deposits under lien to RM8.8 million. Cash and cash equivalents ended at RM14,053,613.2023 年，公司通过私下配售以每股 RM0.195 发行 43,968,600 股新股，筹集 RM8,573,877 用于营运资金。营运活动所用现金净额为 RM1,629,799。借款方面，提取银行承兑汇票 RM2,606,210，偿还定期贷款净额 RM475,055，偿还租赁负债 RM586,149。资本支出为购置物业、厂房及设备 RM80,720 以及使用权资产 RM9,272。一家子公司以 RM1 收购 Solution BioResearch Sdn. Bhd.。抵押存款净增加 RM452,528，使抵押定期存款达 RM8.8 million。期末现金及现金等价物为 RM14,053,613。
Source: annual report 2023, pages 15, 47, 62, 98.出处：2023 年年报第 15、47、62、98 页。
20242024 年
In 2024, net cash used in operating activities increased to RM10,462,665. The group repaid banker's acceptance facilities of RM2,606,210, term loans of RM531,422, and lease liabilities of RM665,010. Capital expenditure was RM99,741 for property, plant and equipment and RM128,128 for right-of-use assets. The company received RM68,250 from the exercise of 390,000 share options at RM0.175 per share. Subsidiaries acquired Solray Sdn. Bhd. for RM1,000 and Pioneer Energy Projects Sdn. Bhd. for RM1, while the company acquired a 30% interest in Solution Edutech Sdn. Bhd. for RM30. A dividend of RM300,000 was paid to a non-controlling interest of a subsidiary. Net deposits under lien released RM1,733,593, leaving RM7.1 million under lien. Cash and cash equivalents fell to RM1.1 million.2024 年，营运活动所用现金净额增至 RM10,462,665。集团偿还了 RM2,606,210 的银行承兑汇票、RM531,422 的定期贷款以及 RM665,010 的租赁负债。资本支出为购置物业、厂房及设备 RM99,741 以及使用权资产 RM128,128。公司因行使 390,000 份购股权（每股 RM0.175）收到 RM68,250。子公司以 RM1,000 收购 Solray Sdn. Bhd.，以 RM1 收购 Pioneer Energy Projects Sdn. Bhd.，公司另以 RM30 收购 Solution Edutech Sdn. Bhd. 30% 股权。向一家子公司的非控股权益支付股息 RM300,000。抵押存款净释放 RM1,733,593，抵押结存余下 RM7.1 million。现金及现金等价物降至 RM1.1 million。
Source: annual report 2024, pages 15, 51, 62, 65, 72, 89, 90.出处：2024 年年报第 15、51、62、65、72、89、90 页。
20252025 年
In 2025, the group incurred a loss before tax of RM25.0 million, primarily attributable to impairment losses of RM19.25 million. Drawdown of banker's acceptance was RM399,477, while term loan repayments were RM388,172 and lease liability repayments were RM747,290. Capital expenditure was RM65,147 for property, plant and equipment and RM16,507 for right-of-use assets. Net withdrawal of deposits under lien released RM1,074,208, leaving RM6.0 million under lien. No new shares were issued and no dividend was proposed. Cash and cash equivalents stood at RM1.4 million.2025 年，集团税前亏损 RM25.0 million，主要归因于年内确认的 RM19.25 million 减值亏损。提取银行承兑汇票 RM399,477，偿还定期贷款 RM388,172，偿还租赁负债 RM747,290。资本支出为购置物业、厂房及设备 RM65,147 以及使用权资产 RM16,507。抵押存款净提取释放 RM1,074,208，抵押结存余下 RM6.0 million。年内未发行新股，亦未建议派发股息。期末现金及现金等价物为 RM1.4 million。
Source: annual report 2025, pages 13, 16, 61, 62, 74.出处：2025 年年报第 13、16、61、62、74 页。
Across the three years三年合看
The board maintained a dividend policy of declaring not less than 0.5 cent per financial year subject to yearly profit after tax of not less than RM4.8 mil; no dividend was declared or paid by the company in 2023, 2024, or 2025. Total liabilities moved from RM29.3 million at end 2023 to RM43.0 million at end 2024 and RM42.3 million at end 2025. The gearing ratio was 6.5% in 2023, 6.7% in 2024, and 10.0% in 2025. Contract assets were RM29.8 million in 2023 and RM30.1 million in 2024 before decreasing to RM7.8 million in 2025, when net impairment losses on trade receivables and contract assets reached RM19,250,289.董事会维持每年派发不少于 0.5 仙股息的政策，前提是年度税后净利不少于 RM4.8 mil；但公司在 2023、2024 与 2025 年均未建议或派发股息。总负债由 2023 年底的 RM29.3 million 增至 2024 年底的 RM43.0 million，2025 年底为 RM42.3 million。负债比率在 2023 年为 6.5%，2024 年为 6.7%，2025 年升至 10.0%。合约资产在 2023 年为 RM29.8 million，2024 年为 RM30.1 million，2025 年降至 RM7.8 million，同年对贸易应收款及合约资产确认的减值损失净额达 RM19,250,289。
Source: annual report 2023, pages 15, 27, 46; annual report 2024, pages 15, 25, 50; annual report 2025, pages 16, 26, 61, 70.出处：2023 年年报第 15、27、46 页；2024 年年报第 15、25、50 页；2025 年年报第 16、26、61、70 页。
Still to be spent尚未支出的款项
From the RM8,573,877 raised from the private placement completed on 3 October 2023, RM6.63 million remained unspent at end 2024, comprising RM4.5 million for research and development of human vaccines and RM2.13 million for working capital. On 24 September 2025, the board approved an extension of time for the utilisation of the balance proceeds to 2 October 2026.在 2023 年 10 月 3 日完成的私下配售所筹集的 RM8,573,877 中，截至 2024 年底仍有 RM6.63 million 尚未动用，包括用于人用疫苗研发的 RM4.5 million 以及用于营运资金的 RM2.13 million。2025 年 9 月 24 日，董事会批准将剩余款项的动用期限延长至 2026 年 10 月 2 日。
Source: annual report 2024, page 48; annual report 2025, page 57.出处：2024 年年报第 48 页；2025 年年报第 57 页。
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| RM令吉 | RM令吉 | RM令吉 | RM令吉 | |
| Revenue营业额 | 33,202,264 | 120,925,088 | 114,972,693 | 28,674,314 |
| Profit/(Loss) before taxation税前盈利（亏损） | (38,579,126) | 5,049,176 | (7,111,233) | (25,025,238) |
| Profit/(Loss) for the financial year本年度盈利（亏损） | (39,354,888) | 2,496,560 | (7,587,796) | (25,882,135) |
| Net cash used in operating activities营运活动所用现金净额 | (28,853,963) | (1,629,799) | (10,462,665) | – |
| Purchase of property, plant and equipment购置物业、厂房及设备 | (772,566) | (80,720) | (99,741) | – |
| Total assets总资产 | 88,260,194 | 113,958,133 | 119,841,626 | 93,286,441 |
| Total equity总权益 | 73,637,484 | 84,707,921 | 76,884,261 | 51,002,146 |
| Borrowings借款 | 5,196,228 | 7,327,383 | 4,189,751 | 4,201,056 |
| Cash and cash equivalents现金及现金等价物 | 6,152,538 | 14,053,613 | 1,102,185 | 1,462,389 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
| What the reports said年报说要做的 | What later reports show之后年报显示的 | Status状态 |
|---|---|---|
| Developing digital twins for physical equipment, aiming to offer them alongside every Solteq product (2023 report)为实体设备开发数字孪生，旨在为每款 Solteq 产品配备该功能（2023 年年报） | Each equipment under the SOLTEQ brand includes the option for a Digital Twin module in the 2024 report.2024 年年报显示，SOLTEQ 品牌下的每台设备均包含数字孪生模块选项。 Source: annual report 2023, page 17; annual report 2024, page 17.出处：2023 年年报第 17 页；2024 年年报第 17 页。 | Carried out已执行 |
| Commercialisation of vaccines from CanSino, including pneumococcal, meningococcal and tuberculosis, can be realised as early as 2025 to 2030 (2023 report)CanSino 疫苗（包括肺炎球菌、脑膜炎球菌和结核病疫苗）最早可在 2025 至 2030 年实现商业化（2023 年年报） | Two product dossiers (MCV4 and PCV13i) were submitted in 2024 targeting market entry in 2026; approvals were anticipated by the end of the third quarter of 2026 in the 2025 report.2024 年已提交两份产品档案（MCV4 与 PCV13i），目标于 2026 年进入市场；2025 年年报显示预计于 2026 年第三季度末获批。 Source: annual report 2023, page 26; annual report 2024, page 25; annual report 2025, pages 25, 26.出处：2023 年年报第 26 页；2024 年年报第 25 页；2025 年年报第 25、26 页。 | Still in progress推进中 |
| Further adoption of the sludge treatment skid planned at BCOT, the Caspian Sea FSO unit, and TCOT (2024 report)计划在 BCOT、里海 FSO 装置及 TCOT 进一步应用油泥处理撬块（2024 年年报） | The 2025 report repeats that further deployment is planned at BCOT, the Caspian Sea FSO unit, and TCOT.2025 年年报再次提及计划在 BCOT、里海 FSO 装置及 TCOT 进一步部署。 Source: annual report 2024, page 20; annual report 2025, page 21.出处：2024 年年报第 20 页；2025 年年报第 21 页。 | Still planned仍在计划中 |
| Registration with Suruhanjaya Tenaga and Gas Malaysia Distribution in progress (2024 report)向能源委员会及 Gas Malaysia Distribution 的注册正在进行中（2024 年年报） | The 2025 report repeats that registration with Suruhanjaya Tenaga and Gas Malaysia Distribution is in progress.2025 年年报仍表示向能源委员会及 Gas Malaysia Distribution 的注册正在进行中。 Source: annual report 2024, page 20; annual report 2025, page 21.出处：2024 年年报第 20 页；2025 年年报第 21 页。 | Still in progress仍在进行中 |
| To utilise RM4.5 million for human vaccine R&D and RM2.13 million for working capital within 24 months from October 2023 (2024 report)自 2023 年 10 月起 24 个月内动用 RM4.5 million 用于人用疫苗研发以及 RM2.13 million 用于营运资金（2024 年年报） | On 24 September 2025, the board approved an extension of time to 2 October 2026 for utilising the balance proceeds.董事会于 2025 年 9 月 24 日批准将剩余款项的动用期限延长至 2026 年 10 月 2 日。 Source: annual report 2024, page 48; annual report 2025, page 57.出处：2024 年年报第 48 页；2025 年年报第 57 页。 | Extended已延期 |
What the reports leave open年报留下待看的事
- Net impairment losses of RM19,250,289 recognised in 2025 on contract assets (RM14,207,993) and trade receivables (RM5,042,296), and the recoverability of remaining contract assets of RM7,777,873.2025 年对合约资产（RM14,207,993）及贸易应收款（RM5,042,296）确认了 RM19,250,289 的减值损失净额，以及剩余 RM7,777,873 合约资产的可收回性。
Source: annual report 2025, pages 70, 73, 138.出处：2025 年年报第 70、73、138 页。
- The planned pivot towards flood mitigation and water management automation projects entering 2026, subject to multi-agency coordination and regulatory approvals.迈入 2026 年计划向防洪及水务管理自动化项目转型，该类项目须经多机构协调及监管批准。
Source: annual report 2025, page 19.出处：2025 年年报第 19 页。
- Regulatory approvals for vaccine candidates MCV4 and PCV13i, anticipated by the end of the third quarter of 2026, with market entry targeted for 2026.MCV4 与 PCV13i 候选疫苗的监管批准进展，预计在 2026 年第三季度末获批，目标于 2026 年进入市场。
Source: annual report 2025, pages 25, 26.出处：2025 年年报第 25、26 页。
- The deployment of the remaining private placement proceeds by the extended deadline of 2 October 2026.剩余私下配售所得款项在延期至 2026 年 10 月 2 日的期限内的使用进展。
Source: annual report 2025, page 57.出处：2025 年年报第 57 页。
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-28.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-10-28。